Aerie Rips 60% After Positive Roclatan Phase 3 Topline Efficacy Results

Shares of Aerie Pharmaceuticals Inc AERI surged more than 65 percent in Wednesday's after-hours session.

The stock was responding to news about its Phase 3 study of Roclatan having met its primary efficacy endpoint.

According to a press release, Roclatan managed to prove statistically superior to each of its components, including the company’s Rhopressa (netarsudil ophthalmic solution) 0.02 percent and the market leading prostaglandin analogue (PGA) latanoprost, in the treatment of patients with maximum baseline intraocular pressures (IOPs) ranging from over 20 to under 36 mmHg (millimeters of mercury).

Roclatan made IOP 1 to 3 mmHg lower than latanoprost or Rhopressa could make it on their own.

On Friday, September 9, Benzinga Pro alerted users about "Unusual Options Activity in Aerie Pharma for Second Day in a Row. Call Activity Suggests Trader Betting Underlying Stock Will Be Over $34 Within Next 60 Days."

Shares traded recently at $34.89, up 64.8 percent after hours. The stock closed at $21.13.

Posted In: BiotechNewsAfter-Hours CenterMoversGeneralRoclatan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...